Clarametyx 2021-01: Efficacy of a Novel Antibody in the Rat Endocarditis Infection Model with Staphylococcus aureus

Project Details

StatusFinished
Effective start/end date4/01/213/01/22

Funding

  • Clarametyx Biosciences, Inc.: $43,870.82